171 related articles for article (PubMed ID: 8838775)
1. The assessment of individual and population bioequivalence.
Chinchilli VM
J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
[TBL] [Abstract][Full Text] [Related]
2. The analysis of bioequivalence with respect to TMAX under a 2 x 2 crossover design.
Have TR; Ten Chinchilli VM
J Biopharm Stat; 1995 Jul; 5(2):185-99. PubMed ID: 7581427
[TBL] [Abstract][Full Text] [Related]
3. Analysis of multiple-dose bioequivalence studies.
Chinchilli VM; Esinhart JD; Barr WH
J Biopharm Stat; 1994 Nov; 4(3):423-35. PubMed ID: 7881454
[TBL] [Abstract][Full Text] [Related]
4. Tests for individual and population bioequivalence based on generalized p-values.
McNally RJ; Iyer H; Mathew T
Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
[TBL] [Abstract][Full Text] [Related]
5. On assessment of bioequivalence under a higher-order crossover design.
Chow SC; Liu JP
J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
[TBL] [Abstract][Full Text] [Related]
6. The subject-by-formulation interaction in multivariate bioequivalence.
Cao L; Mathew T
J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
[TBL] [Abstract][Full Text] [Related]
7. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
Esinhart JD; Chinchilli VM
J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
[TBL] [Abstract][Full Text] [Related]
8. The impact of outlying subjects on decision of bioequivalence.
Ki FY; Liu JP; Wang W; Chow SC
J Biopharm Stat; 1995 Mar; 5(1):71-94. PubMed ID: 7613561
[TBL] [Abstract][Full Text] [Related]
9. Average bioequivalence for two-sequence two-period crossover design with incomplete data.
Lee JY; Kim BC; Park SG
J Biopharm Stat; 2005; 15(5):857-67. PubMed ID: 16078389
[TBL] [Abstract][Full Text] [Related]
10. A three-step procedure for assessing bioequivalence in the general mixed model framework.
Vuorinen J; Turunen J
Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
[TBL] [Abstract][Full Text] [Related]
11. Assessing individual bioequivalence using the structural equation model.
Carrasco JL; Jover L
Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
[TBL] [Abstract][Full Text] [Related]
12. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
[TBL] [Abstract][Full Text] [Related]
13. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study].
Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ
Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315
[TBL] [Abstract][Full Text] [Related]
14. A modified large sample approach in the assessment of population bioequivalence.
Quiroz J; Ting N; Wei GC; Burdick RK
J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
[TBL] [Abstract][Full Text] [Related]
15. Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses.
Tröger U; Martens J; Meyer FP; Hoffmann A; Terhaag B
Arzneimittelforschung; 1995 Dec; 45(12):1266-70. PubMed ID: 8595082
[TBL] [Abstract][Full Text] [Related]
16. A new approach for outliers in a bioavailability/bioequivalence study.
Liao JJ
J Biopharm Stat; 2007; 17(3):393-405. PubMed ID: 17479389
[TBL] [Abstract][Full Text] [Related]
17. Assessing bioequivalence using genomic data.
Chow SC; Shao J; Li L
J Biopharm Stat; 2004 Nov; 14(4):869-80. PubMed ID: 15587969
[TBL] [Abstract][Full Text] [Related]
18. Types of bioequivalence and related statistical considerations.
Hauck WW; Anderson S
Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
[TBL] [Abstract][Full Text] [Related]
19. A distribution-free procedure for the statistical analysis of bioequivalence studies.
Hauschke D; Steinijans VW; Diletti E
Int J Clin Pharmacol Ther Toxicol; 1990 Feb; 28(2):72-8. PubMed ID: 2307548
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]